Study Protocol
Published on 15 Jul 2022
Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods
in Aging Psychiatry
- 3,749 views
- 1 citation